Lyka Labs Ltd vs Vista Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Lyka Labs Ltd is ₹ 58.72 as of 05 May 15:30 . The P/E Ratio of Lyka Labs Ltd changed from 10 on March 2022 to 45.1 on March 2025 . This represents a CAGR of 45.73% over 4 yearsThe P/E Ratio of Vista Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Lyka Labs Ltd changed from ₹ 74.59 crore on March 2021 to ₹ 360.29 crore on March 2025 . This represents a CAGR of 37.02% over 5 yearsThe Market Cap of Vista Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Lyka Labs Ltd for the Dec '25 is ₹ 31.89 crore as compare to the Sep '25 revenue of ₹ 37.75 crore. This represent the decline of -15.52% The revenue of Vista Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Lyka Labs Ltd for the Dec '25 is ₹ 2.81 crore as compare to the Sep '25 ebitda of ₹ -1.45 crore. This represent the decline of -293% The ebitda of Vista Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Lyka Labs Ltd changed from ₹ 1.29 crore to ₹ -0.15 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Vista Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Lyka Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vista Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Lyka Labs Ltd

Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83.
It also added a range of ayurvedic and animal health care products over the years.
In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan.
Lyka Exports is the subsidiary of the company.
The Company is engaged in the development, manufacture and marketing of quality finished dosages. The company offers a broad range of antibiotics used as life-savers and to treat minor infections.

About Vista Pharmaceuticals Ltd

Vista Pharmaceuticals Limited was incorporated on January 25,1991 with the Registrar of Companies, Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7, 1991.
The Company is engaged in the formulation of pharmaceutical products.
It offers a range of products mainly into the therapeutic areas of gastrointestinal, pain management and anti-infection, catering to common ailments.
This division is a primary contributor to the domestic sales of Torrent Pharmaceuticals Ltd., based in Hyderabad, India. The Company was in process of setting up a 100% EOU for manufacture of drug formulations with an installed capacity of 400 million tablets & 200 million capsules per annum.
Apart from these, the Company offers over the counter & prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories.

FAQs for the comparison of Lyka Labs Ltd and Vista Pharmaceuticals Ltd

Which company has a larger market capitalization, Lyka Labs Ltd or Vista Pharmaceuticals Ltd?

Market cap of Lyka Labs Ltd is 209 Cr while Market cap of Vista Pharmaceuticals Ltd is 49 Cr

What are the key factors driving the stock performance of Lyka Labs Ltd and Vista Pharmaceuticals Ltd?

The stock performance of Lyka Labs Ltd and Vista Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lyka Labs Ltd and Vista Pharmaceuticals Ltd?

As of May 5, 2026, the Lyka Labs Ltd stock price is INR ₹58.72. On the other hand, Vista Pharmaceuticals Ltd stock price is INR ₹7.98.

How do dividend payouts of Lyka Labs Ltd and Vista Pharmaceuticals Ltd compare?

To compare the dividend payouts of Lyka Labs Ltd and Vista Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.